Danoprevir (ITMN-191)
For research use only.
Catalog No.S1183 Synonyms: RG7227
11 publications
Molecular Weight(MW): 731.83
Danoprevir (ITMN-191, RG7227) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
5 Customer Reviews
-
Western blot analysis of HCV NS3 protease cleavage of MAVS. The catalytic efficiency of four proteases (H, H-A156T, 41 and 41-A156T) from individuals H and 41 were tested in the absence or presence of an NS3 protease inhibitor (danoprevir). Expression of the HCV NS3 proteases resulted in cleavage of the lambda cI repressor with MAVS cleavage site. Expression of the protease was induced with IPTG for 3 h. The lambda cI repressor with MAVS cleavage site was not cleaved by an NS3 protease that included a substitution in catalytic residue S139A. Similarly, different catalytic efficiencies were observed with different proteases.
Mol Biol Evol 2014 31(6), 1546-53. Danoprevir (ITMN-191) purchased from Selleck.
Suppression of HCV replication by anti-HCV inhibitors. HCV-Feo replicon-containing cells were seeded in 96-well plates at a density of 1 x 104 cells/well. Twenty-four hours later, cells were exposed to the indicated concentrations of danoprevir. After a 72-hour treatment with inhibitors, cells were harvested and firefly luciferase activity was measured. Results are the means and SDs of three independent experiments (upper panels). PrestoBlue cell viability reagent (Invitrogen, CA) was used to examine the cytotoxic effect of inhibitors according to the manufacturer's recommendations. Data are the means and SDs of three independent experiments (lower panels).
Antimicrob Agents Chemother 2012 56(10), 5365-73. Danoprevir (ITMN-191) purchased from Selleck.
-
Inhibition of HCV and CHV NS3/4A proteases in the presence of the protease inhibitors (A) 25a or (B) danoprevir. The graph illustrates the relative (%) lambda phage titer after selective growth of lambda in E. coli cells coexpressing the NS3/4A protease constructs and the lambda cI repressor expressing either MAVS or TRIF cleavage sites in the absence or presence of protease inhibitors (20 mM). No significant inhibition was detected with an HCV NS3/4A protease mutant carrying the substitution D168V, which confers resistance to protease inhibitors. Values are the means 6 standard deviations (error bars) of at least three experiments.
PLoS One 2012 7, e42481. Danoprevir (ITMN-191) purchased from Selleck.
Effects of TNFα, etanercept, and danoprevir on HCV infection in HFLC. Cells (n=6 wells/condition) were treated with TNFα (20 ng/ml) ± etanercept (1 μg/ml), danoprevir (2 μM), or media control before and during infection with Jc1G. Secreted luciferase was measured 96 hours after the start of infection. Box-and-whiskers plot; whiskers represent minimum and maximum values. Values of p were calculated by one-way ANOVA. ***, p < 0.001; ****, p < 0.0001
Gastroenterology, 2017, 153(2):566-578. Danoprevir (ITMN-191) purchased from Selleck.
-
Antiviral Res, 2018, 150:79-92. Danoprevir (ITMN-191) purchased from Selleck.
Purity & Quality Control
Choose Selective HCV Protease Inhibitors
Biological Activity
| Description | Danoprevir (ITMN-191, RG7227) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2. | ||
|---|---|---|---|
| Features | A peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV). | ||
| Targets |
|
||
| In vitro |
Danoprevir (0.29 nM) inhibits the reference genotype 1 NS3/4A protease half-maximally, but a high dose of Danoprevir (10 μM) shows no appreciably inhibition in a panel of 79 proteases, ion channels, transporters, and cell surface receptors. Danoprevir remains bound to and inhibits NS3/4A for more than 5 hours after its initial association. Danoprevir (45 nM) eliminates a patient-derived HCV genotype 1b replicon from hepatocyte-derived Huh7 cells with an EC50 of 1.8 nM. [1] In HCV subgenomic replicon cell lines containing the individual mutations, V36M, R109K, and V170A substitutions confer little or no resistance to Danoprevir, but the R155K substitution confers a high level (62-fold increase) of resistance to Danoprevir. [2] In Huh7.5 cells transfected with chimeric recombinant virus, Danoprevir shows antiviral inhibition effects against HCV genotypes 1, 4 and 6 with IC50 of 2-3 nM, which are >100-fold lower than genotypes 2/3/5 (280-750 nM). [3] |
||
| In vivo | Danoprevir (30 mg/kg) administered to rats or monkeys shows that its concentrations in liver 12 hours after dosing exceed the Danoprevir concentration required to eliminate replicon RNA from cells. [1] |
Protocol
| Kinase Assay:[1] |
- Collapse
Continuous fluorescent resonance energy transfer (FRET) assay: The assay buffer contains 25 μM NS4A peptide, 50 mM Tris-HCl, pH 7.5, 15% (vol/vol) glycerol, 0.6 mM lauryldimethylamine N-oxide, 10 mM dithiothreitol, and 0.5 μM fluorescein/QXL520-labeled FRET substrate {Ac-DE-Dap(QXL520)-EE-Abu-ψ-[COO]-AS-Cys(5-FAMsp)-NH2}. K2040 enzyme (50 pM) is added to initiate the reaction. Reactions are set up in black 96-well plates, and fluorescence data is collected. Control reactions lacking inhibitors and enzyme are included. Initial rates are calculated from the linear phase of the reaction (up to 1 hour) and are used to obtain IC50. Recovery of activity from preformed Danoprevir-NS3/4A complex is assessed by preincubating 10 nM NS3/4A with a two-fold excess of Danoprevir in 1× assay buffer for 15 min, followed by a rapid 200-fold dilution of the preformed complex into assay buffer containing substrate. A control reaction with the same final conditions without preincubation of NS3/4A and Danoprevir is initiated by the addition of enzyme to an otherwise-complete reaction mixture. Additional control reactions lack either Danoprevir or NS3. The progress of the reactions is followed over 5 hours. |
|---|---|
| Cell Research:[1] |
- Collapse
|
| Animal Research:[1] |
- Collapse
|
Solubility (25°C)
| In vitro | DMSO | 144 mg/mL (196.76 mM) |
|---|---|---|
| Water | Insoluble | |
| Ethanol | ''144 mg/mL |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 731.83 |
|---|---|
| Formula | C35H46FN5O9S |
| CAS No. | 850876-88-9 |
| Storage |
powder in solvent |
| Synonyms | RG7227 |
| Smiles | CC(C)(C)OC(=O)NC1CCCCCC=CC2CC2(NC(=O)C3CC(CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6 |
In vivo Formulation Calculator (Clear solution)
| Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment) | ||||||||||
| Dosage | mg/kg |  |
Average weight of animals | g | |
Dosing volume per animal | ul | |
Number of animals | |
| Step 2: Enter the in vivo formulation () | ||||||||||
| % DMSO % % Tween 80 % ddH2O | ||||||||||
| CalculateReset | ||||||||||
Calculation results:
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT01714154 | Completed | Drug: danoprevir|Drug: ritonavir|Drug: setrobuvir | Healthy Volunteer | Hoffmann-La Roche | November 2012 | Phase 1 |
| NCT01592318 | Completed | Drug: danoprevir|Drug: ritonavir | Healthy Volunteer | Hoffmann-La Roche | May 2012 | Phase 1 |
| NCT01588002 | Completed | Drug: danoprevir|Drug: efavirenz|Drug: ritonavir | Healthy Volunteer | Hoffmann-La Roche | April 2012 | Phase 1 |
| NCT01519336 | Completed | Drug: danoprevir|Drug: darunavir|Drug: ritonavir | Healthy Volunteer | Hoffmann-La Roche | February 2012 | Phase 1 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
